Zynerba Pharmaceuticals Future Growth

Future criteria checks 5/6

Zynerba Pharmaceuticals is forecast to grow earnings and revenue by 67.2% and 72% per annum respectively while EPS is expected to grow by 59% per annum.

Key information

67.2%

Earnings growth rate

59.0%

EPS growth rate

Pharmaceuticals earnings growth	19.6%
Revenue growth rate	72.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	16 Aug 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0M40 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	48	-24	-34	-32	3
12/31/2024	11	-49	-58	-56	4
12/31/2023	N/A	-43	-36	-36	4
6/30/2023	N/A	-38	-32	-32	N/A
3/31/2023	N/A	-37	-31	-31	N/A
12/31/2022	N/A	-35	-23	-23	N/A
9/30/2022	N/A	-36	-25	-25	N/A
6/30/2022	N/A	-38	-26	-26	N/A
3/31/2022	N/A	-38	-25	-25	N/A
12/31/2021	N/A	-37	-34	-33	N/A
9/30/2021	N/A	-38	-33	-33	N/A
6/30/2021	N/A	-37	-35	-35	N/A
3/31/2021	N/A	-47	-39	-39	N/A
12/31/2020	N/A	-51	-42	-41	N/A
9/30/2020	N/A	-52	-42	-42	N/A
6/30/2020	N/A	-45	-41	-40	N/A
3/31/2020	N/A	-36	-37	-36	N/A
12/31/2019	N/A	-33	-35	-35	N/A
9/30/2019	0	-30	-34	-34	N/A
6/30/2019	0	-36	-30	-29	N/A
3/31/2019	0	-37	-32	-32	N/A
12/31/2018	0	-40	-33	-32	N/A
9/30/2018	N/A	-40	-33	-33	N/A
6/30/2018	N/A	-41	-30	-30	N/A
3/31/2018	N/A	-37	-29	-29	N/A
12/31/2017	N/A	-32	-26	-26	N/A
9/30/2017	N/A	-31	-25	-25	N/A
6/30/2017	N/A	-28	-27	-26	N/A
3/31/2017	N/A	-26	N/A	-23	N/A
12/31/2016	0	-23	N/A	-20	N/A
9/30/2016	0	-22	N/A	-18	N/A
6/30/2016	0	-20	N/A	-16	N/A
3/31/2016	0	-15	N/A	-13	N/A
12/31/2015	0	-13	N/A	-10	N/A
9/30/2015	0	-9	N/A	-8	N/A
6/30/2015	1	-7	N/A	-6	N/A
3/31/2015	1	-7	N/A	-5	N/A
12/31/2014	1	-6	N/A	-4	N/A
9/30/2014	1	-5	N/A	-2	N/A
12/31/2013	1	-1	N/A	0	N/A
12/31/2012	1	-1	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0M40 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.4%).

Earnings vs Market: 0M40 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 0M40 is expected to become profitable in the next 3 years.

Revenue vs Market: 0M40's revenue (72% per year) is forecast to grow faster than the UK market (4% per year).

High Growth Revenue: 0M40's revenue (72% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 0M40's Return on Equity is forecast to be high in 3 years time

Zynerba Pharmaceuticals Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Recent updates

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

New minor risk - Profitability

Zynerba Pharmaceuticals Provides Nasdaq Compliance Update

New major risk - Financial position

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Forecast to breakeven in 2025

Zynerba Pharmaceuticals Gets an Additional 180 Calendar Day Period, or Until October 30, 2023 to Regain Compliance with the Bid Price Rule

Insufficient new directors

Insufficient new directors

Zynerba Pharmaceuticals Announces Update on Reconnect, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the Annual Meeting of the American College of Neuropsychopharmacology

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel(TM) in the Journal of Neurodevelopmental Disorders

Zynerba Pharmaceuticals Receives a Deficiency Letter from Nasdaq

Zynerba Pharmaceuticals, Inc. Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the National Organization for Rare Disorders (Nord) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals, Inc. Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome At the International Society for Autism Research Annual Meeting

Insufficient new directors

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces European Commission Grants Orphan Drug Designation for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Trial of Zygel in 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Announces Executive Changes

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

Pomerantz LLP and The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement Against Zynerba Pharmaceuticals, Inc

Forecast to breakeven in 2025

Zynerba Pharmaceuticals, Inc. Receives Guidance from the U.S. Food and Drug Administration on Confirmatory Phase 3 Trial of Zygel in Patients with Fragile X Syndrome

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies